A new drug has shown significant results in treating pancreatic cancer, with some reports describing the outcomes as "unprecedented" and a "landmark" achievement. The drug, which targets a specific mutation, has been successful in a late-stage trial, with some outlets noting it has doubled survival time for patients. Doctors are now considering potential uses for the drug beyond pancreatic cancer treatment.